受强制性开放获取政策约束的文章 - Joshua Bauml了解详情
无法在其他位置公开访问的文章：2 篇
Increased rate of recurrence and high rate of salvage in patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma with adverse features treated with …
RM Carey, D Shimunov, GS Weinstein, SB Cannady, JN Lukens, A Lin, ...
Head & neck 43 (4), 1128-1141, 2021
强制性开放获取政策： US National Institutes of Health
Unsupervised exercise in survivors of human papillomavirus related head and neck cancer: how many can go it alone?
J Bauml, J Kim, X Zhang, C Aggarwal, RB Cohen, K Schmitz
Journal of Cancer Survivorship 11, 462-468, 2017
强制性开放获取政策： US National Institutes of Health
可在其他位置公开访问的文章：40 篇
Amivantamab in EGFR exon 20 insertion–mutated non–small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study
K Park, EB Haura, NB Leighl, P Mitchell, CA Shu, N Girard, S Viteri, ...
Journal of Clinical Oncology 39 (30), 3391-3402, 2021
强制性开放获取政策： National Institute for Health Research, UK
Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non–small cell lung cancer
C Aggarwal, JC Thompson, TA Black, SI Katz, R Fan, SS Yee, AL Chien, ...
JAMA oncology 5 (2), 173-180, 2019
强制性开放获取政策： US National Institutes of Health
Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA
JC Thompson, SS Yee, AB Troxel, SL Savitch, R Fan, D Balli, ...
Clinical Cancer Research 22 (23), 5772-5782, 2016
强制性开放获取政策： US National Institutes of Health
Pembrolizumab after completion of locally ablative therapy for oligometastatic non–small cell lung cancer: a phase 2 trial
JM Bauml, R Mick, C Ciunci, C Aggarwal, C Davis, T Evans, ...
JAMA oncology 5 (9), 1283-1290, 2019
强制性开放获取政策： US National Institutes of Health
Immunotherapy targeting HPV16/18 generates potent immune responses in HPV-associated head and neck cancer
C Aggarwal, RB Cohen, MP Morrow, KA Kraynyak, AJ Sylvester, ...
Clinical Cancer Research 25 (1), 110-124, 2019
强制性开放获取政策： US National Institutes of Health
Cisplatin every 3 weeks versus weekly with definitive concurrent radiotherapy for squamous cell carcinoma of the head and neck
JM Bauml, R Vinnakota, YH Anna Park, SE Bates, T Fojo, C Aggarwal, ...
JNCI: Journal of the National Cancer Institute 111 (5), 490-497, 2019
强制性开放获取政策： US National Institutes of Health
Do attitudes and beliefs regarding complementary and alternative medicine impact its use among patients with cancer? A cross‐sectional survey
JM Bauml, S Chokshi, MM Schapira, EO Im, SQ Li, CJ Langer, SA Ibrahim, ...
Cancer 121 (14), 2431-2438, 2015
强制性开放获取政策： US National Institutes of Health
Scan-associated distress in lung cancer: quantifying the impact of “scanxiety”
JM Bauml, A Troxel, CN Epperson, RB Cohen, K Schmitz, C Stricker, ...
Lung Cancer 100, 110-113, 2016
强制性开放获取政策： US National Institutes of Health
A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours
A Maity, R Mick, AC Huang, SM George, MD Farwell, JN Lukens, ...
British journal of cancer 119 (10), 1200-1207, 2018
强制性开放获取政策： US National Institutes of Health
Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist?
J Bauml, R Mick, Y Zhang, CD Watt, A Vachani, C Aggarwal, T Evans, ...
Lung cancer 81 (3), 347-353, 2013
强制性开放获取政策： US National Institutes of Health
Baseline plasma tumor mutation burden predicts response to pembrolizumab-based therapy in patients with metastatic non–small cell lung cancer
C Aggarwal, JC Thompson, AL Chien, KJ Quinn, WT Hwang, TA Black, ...
Clinical Cancer Research 26 (10), 2354-2361, 2020
强制性开放获取政策： US National Institutes of Health, LUNGevity Foundation, USA
Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non–Small-Cell Lung Cancer
C Aggarwal, CW Davis, R Mick, JC Thompson, S Ahmed, S Jeffries, ...
JCO precision oncology 2, 1-29, 2018
强制性开放获取政策： US National Institutes of Health
Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non–Small-Cell Lung …
E Bange, ME Marmarelis, WT Hwang, YX Yang, JC Thompson, ...
JCO precision oncology 3, 1-11, 2019
强制性开放获取政策： US National Institutes of Health
ROS1 gene rearrangements are associated with an elevated risk of peridiagnosis thromboembolic events
TL Ng, DE Smith, R Mushtaq, T Patil, A Dimou, S Yang, Q Liu, X Li, ...
Journal of Thoracic Oncology 14 (4), 596-605, 2019
强制性开放获取政策： US National Institutes of Health
Serial monitoring of circulating tumor DNA by next-generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving pembrolizumab …
JC Thompson, EL Carpenter, BA Silva, J Rosenstein, AL Chien, K Quinn, ...
JCO Precision Oncology 5, 510-524, 2021
强制性开放获取政策： US National Institutes of Health, LUNGevity Foundation, USA
Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia?
J Bauml, L Chen, J Chen, J Boyer, M Kalos, SQ Li, A DeMichele, JJ Mao
Breast Cancer Research 17, 1-8, 2015
强制性开放获取政策： US National Institutes of Health
Determinants of survival in advanced non–small-cell lung cancer in the era of targeted therapies
J Bauml, R Mick, Y Zhang, CD Watt, A Vachani, C Aggarwal, T Evans, ...
Clinical lung cancer 14 (5), 581-591, 2013
强制性开放获取政策： US National Institutes of Health
Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib
JM Bauml, BT Li, V Velcheti, R Govindan, A Curioni-Fontecedro, C Dooms, ...
Lung cancer 166, 270-278, 2022
强制性开放获取政策： US National Institutes of Health
出版信息和资助信息由计算机程序自动确定